Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ECTRIMS 2023 | Neuroprotective role of estrogens in MS

Rhonda Voskuhl, MD, University of California, Los Angeles, CA, discusses the neuroprotective benefits of estrogens in multiple sclerosis (MS) treatment. The speaker emphasizes that certain estrogens, targeting the β receptors rather than the α receptors, can mitigate off-target effects like those on breast tissue. Drawing parallels with drug dosing, such as interferon variations, Dr Voskuhl highlights the importance of type, timing, and dose in hormone replacement therapy benefits. An exploration into estriol demonstrated its potential in treating MS, especially during menopause when disabilities worsen. The upcoming multicenter trial aims to administer estriol at mid-pregnancy doses, focusing on preventing cerebral cortex atrophy and enhancing cognition. Dr Voskuhl underscores the need to go beyond treating short-term menopausal symptoms like hot flashes, focusing instead on addressing neurodegenerative mechanisms for long-term benefits. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2023 in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


I am an inventor on patents own by the University of California, Los Angeles (UCLA) related to estriol treatment for neuroprotection licensed by CleopatraRX and for estrogen receptor beta ligand treatment for neuroprotection (unlicensed).